Netflix Is Earning More Than Ever. The Stock Is Down 37%. Both Things Are True.
The gist of it The filed numbers show a business that has nearly doubled its profit margin in four years...
Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.
The gist of it The filed numbers show a business that has nearly doubled its profit margin in four years...
A company reports an operating loss of more than $10 billion in a single quarter. Its stock sits within striking...
Amgen built its modern commercial identity on drugs that strengthen bones and suppress immune systems. For years, Prolia and Xgeva,...
Honeywell Technologies announced a leadership reshuffle on Aug. 19, 2026, promoting Billal Hammoud from President and CEO of Building Autom
Lowe's Companies narrowed its fiscal 2026 earnings outlook on Wednesday, reducing adjusted diluted EPS guidance to approximately $12.25 fro
The standing BullScope yardsticks for Goldman Sachs Group, computed from official filings and refreshed with each new edition.
For most of the past decade, Lowe's has been a story of patient reinvention. The company spent years losing ground...
Goldman Sachs spent most of the last decade trading below the value of its own assets. After the 2008 crisis,...
America's debt hits $40 trillion any day now. Interest alone runs $3.8 billion a day. The last time the hole...
The standing BullScope yardsticks for Deere &, computed from official filings and refreshed with each new edition.
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer